Inactivated and subunit vaccines to prevent shigellosis (Q37640115)

21 August 2017

1 reference

title

Inactivated and subunit vaccines to prevent shigellosis (English)

1 reference

21 August 2017

Robert W Kaminski

1

1 reference

PubMed ID

19943764

21 August 2017

Edwin V Oaks

series ordinal

2

1 reference

21 August 2017

1 December 2009

1 reference

Expert Review of Vaccines

21 August 2017

1 reference

21 August 2017

8

1 reference

21 August 2017

12

1 reference

21 August 2017

1693-1704

1 reference

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Live-attenuated Shigella vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Inoculum size in shigellosis and implications for expected mode of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Interaction of Ipa proteins of Shigella flexneri with alpha5beta1 integrin promotes entry of the bacteria into mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigella flexneri induces apoptosis in infected macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

IpaB mediates macrophage apoptosis induced by Shigella flexneri

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Macrophage apoptosis in microbial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Human monocytes kill Shigella flexneri but then die by apoptosis associated with suppression of proinflammatory cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

A novel caspase-1/toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Intracellular type III secretion by cytoplasmic Shigella flexneri promotes caspase-1-dependent macrophage cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Supramolecular structure of the Shigella type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Liposomes recruit IpaC to the Shigella flexneri type III secretion apparatus needle as a final step in secretion induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Optimization of virulence functions through glucosylation of Shigella LPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

A role for Nod-like receptors in autophagy induced by Shigella infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

ShiA abrogates the innate T-cell response to Shigella flexneri infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

The ShiA protein encoded by the Shigella flexneri SHI-2 pathogenicity island attenuates inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Identification of chromosomal Shigella flexneri genes induced by the eukaryotic intracellular environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

IcsA surface presentation in Shigella flexneri requires the periplasmic chaperones DegP, Skp, and SurA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Structural organization of the needle complex of the type III secretion apparatus of Shigella flexneri

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Future vaccine development at NICHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Shigellosis: the current status of vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Vaccine potential for inactivated shigellae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Bacterial ghosts--biological particles as delivery systems for antigens, nucleic acids and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Iron and virulence in Shigella

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Anaerobic regulation of Shigella flexneri virulence: ArcA regulates Fur and iron acquisition genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Vaccines against cholera, typhoid fever and shigellosis for developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Immunological evidence for functional rather than structural mimicry by a Shigella flexneri Y polysaccharide-mimetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Mucosal adjuvant properties of the Shigella invasin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.127

21 January 2018

Identifiers

DOI

10.1586/ERV.09.127

1 reference

21 August 2017

1 reference

PubMed ID

19943764